Fatty acid derivatives of the formula (I)

##STR00001##

wherein R.sup.1 is an aliphatic group containing 1 to 17 carbon atoms, which is linear, branched, saturated or unsaturated; R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, R.sup.7 are, independently, hydrogen, methyl, ethyl or hydroxymethyl; m, n and p are numbers from 0 to 17, with the proviso that m+n+p1, and m+n+p<18 where the different monomers can be arranged in statistical order, alternatingly or as a block copolymer and m, n and p can be a statistical mixture; X is, independently, a covalent bond or hydroxy methylene; R.sup.8 is an aliphatic group containing 1 to 10 carbon atoms, which is linear, branched, cyclic, saturated or unsaturated, substituted or unsubstituted phenyl or substituted or unsubstituted benzyl,
are useful as herbicides.

Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

Provided are prodrugs of gamma-hydroxybutyric acid as well as compositions and uses thereof.

A compound has the structure of formula (1): X(OCH.sub.2CH.sub.2CH.sub.2).sub.nOR (1) in which n is an integer from 2 to 15, R is a C.sub.6 to C.sub.36 hydrocarbyl group, X is R or R.sub.1C(O) and R.sub.1 is a C.sub.2 to C.sub.36 hydrocarbyl group. A personal care product contains the compound of formula (1). A method of producing the compound and the use of the compound as a sensory agent and/or pigment wetting agent in a cosmetic or personal care product are also disclosed.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

The present disclosure provides treprostinil derivatives that can act as prodrugs of treprostinil. The treprostinil derivatives can be used to treat any conditions responsive to treatment with treprostinil, including pulmonary hypertension, such as pulmonary arterial hypertension.

A process for the transesterification of methyl-2-ethylhexanoate with triethylene glycol to produce triethylene glycol di-2-ethylhexanoate is provided. In the process, methyl-2-ethylhexanoate is combined with triethylene glycol to form a first mixture. The first mixture is heated in the presence of a catalyst to form a second mixture comprising methanol and triethylene glycol di-2-ethylhexanoate. Methanol is separated from the second mixture to yield triethylene glycol di-2-ethylhexanoate. Na.sub.2CO.sub.3, Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, Rb.sub.2CO.sub.3, sodium methoxide or titanium isopropoxide are suitable catalysts.

A process for the transesterification of methyl-2-ethylhexanoate with triethylene glycol to produce triethylene glycol di-2-ethylhexanoate is provided. In the process, methyl-2-ethylhexanoate is combined with triethylene glycol to form a first mixture. The first mixture is heated in the presence of a catalyst to form a second mixture comprising methanol and triethylene glycol di-2-ethylhexanoate. Methanol is separated from the second mixture to yield triethylene glycol di-2-ethylhexanoate. Na.sub.2CO.sub.3, Cs.sub.2CO.sub.3, K.sub.2CO.sub.3, Rb.sub.2CO.sub.3, sodium methoxide or titanium isopropoxide are suitable catalysts.